F&P Healthcare humidification products will drive earnings, Morningstar says
Fisher & Paykel Healthcare Corp.’s respiratory humidification business, which lagged behind sleep apnea sales in the first half, will probably drive earnings growth through the remainder of the year as the company rolls out new products.
Obstructive sleep apnea, or OSA products were the company’s “star performer” in the first half, achieving 20% growth in constant currency terms, said Morningstar analyst Nachi Moghe, who rates the stock ‘accumulate.’
“We think the company will continue to achieve strong growth in the region of between 18 – 20% in the second half,” he said in a Nov. 24 report. “FPH has a strong product pipeline which we think will enable it to gain market share.”
F&P Healthcare garners equal amounts of revenue from OSA products and its respiratory and acute care (RH) products. The latter’s performance is expected to grow “incrementally” and remain in the double digits throughout the second half, eventually becoming the main contributor, Moghe said.
The company plans to expand its current range of masks and launch new flow generators, while declines in prices of OSA products “seem to have stabilized” he said.
“We think FPH is firing on all cylinders”
Shares of F&P Healthcare rose 0.9% to $3.20 on the NZX today and have climbed about 4% in the past month, while the NZX 50 fell 2%.
The company gets almost 80% of its revenue in U.S. dollars and has enjoyed growth in North America amid growing awareness of the link between sleep apnea and health conditions including heart disease.
Net profit after tax grew 31% to $37 million in the first half, boosted by a weaker New Zealand dollar and solid underlying growth. Gross margin dropped 140 basis points due to an adverse sales mix.
Businesswire.co.nz
Related News
F&P Healthcare commits to third Auckland building as part of $33M spending plan Daily ShareChat: Fisher & Paykel Healthcare Record profit for Fisher & Paykel Healthcare - outlook strong F&P Healthcare trims $23m of debt F&P Healthcare forecasts 25% gain in 2010 profit on sales growth Daily ShareChat: Fisher & Paykel Healthcare Daily ShareChat: Fisher & Paykel Healthcare F&P Healthcare stocks drops as profit forecast misses estimates F&P Healthcare posts 76% profit jump on weaker kiwi, respirator sales Daily ShareChat: Fisher & Paykel Healthcare
NZX Annoucements for FPH
|
|
Fisher & Paykel Healthcare Corporation Limited Ord Shares
Current quote:
FPH $3.30
Quotes delayed 20 minutes
Price when article published: $3.21
Previous News
Sharemarket News By Email
Stock Quote
At a Glance
| NZX 50 Index |
3227.70 |
 |
4.30 |
| S&P/ASX 200 |
4814.20 |
 |
0.00 |
| Dow Jones Industrials |
10611.80 |
 |
44.50 |
Comment & Analysis
|
“
Things are moving so fast in the markets and global economies that most writers I follow are complaining of the same thing – there is so much of value being written that it is near impossible to keep up. When top writers such as John Mauldin and George Friedman complain of the volume of [...]
”
Wayne Lochore More »
|
|
|
|


NZX 15 Index
NZX Announcements
|